← Eichor
Condition: Colo Rectal Cancer Dmmr Msi H Crc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Colo Rectal Cancer Dmmr Msi H Crc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT05236972Neoadjuvant Toripalimab With or Without Celecoxib in dMMR/MSI-H Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT03926338Toripalimab Plus Celecoxib for dMMR/MSI-H Locally Advanced Colorectal Cancer
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06903858The Efficacy of Watch and Wait Strategy or Surgery After Neoadjuvant Immunotherapy for Locally Advanced Colorectal Cance
Phase N/A · 1 location(s) · Yunnan Cancer Hospital · NCT06477991KN035 for dMMR/MSI-H Advanced Solid Tumors
Phase 2 · 1 location(s) · 3D Medicines (Sichuan) Co., Ltd. · NCT03667170Prospective National Cohort Evaluating Predictive Biomarkers of Resistance to Immunotherapy in Patients With MSI/dMMR Me
Phase N/A · 20 location(s) · Federation Francophone de Cancerologie Digestive · NCT06353854A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 an
Phase 2 · 39 location(s) · Ono Pharmaceutical Co., Ltd. · NCT06948448Circulating Tumor DNA (ctDNA) as a Predictive Biomarker for Immunotherapy in Advanced or Locally Advanced dMMR/MSI-H Col
Phase N/A · 2 location(s) · Geneplus-Beijing Co. Ltd. · NCT06098560A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer
Phase 1/Phase 2 · 22 location(s) · GlaxoSmithKline · NCT07213609Adjuvant PD-1 Blockade for High-risk Stage-II DMMR/MSI-H Colorectal Cancer
Phase 3 · 1 location(s) · Sun Yat-sen University · NCT06520683Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Phase 1/Phase 2 · 7 location(s) · Neonc Technologies, Inc. · NCT06047379Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
Phase 2 · 2 location(s) · University of Iowa · NCT05239546A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692Phase Ⅱ Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
Phase 2 · 1 location(s) · Fudan University · NCT07003022Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer
Phase 3 · 1 location(s) · Akeso · NCT07412613Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
Phase N/A · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07352280Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
Phase 2 · 1 location(s) · Diwakar Davar · NCT07223424EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combinatio
Phase 1/Phase 2 · 10 location(s) · Eikon Therapeutics · NCT07262619Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Phase N/A · 8 location(s) · Elephas · NCT07327489Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 15 location(s) · MOMA Therapeutics · NCT06974110Different Cycles of Preoperative Neoadjuvant Sintilimab in Mismatch-repair Deficient/microsatellite Instability-high, Lo
Phase 2 · 1 location(s) · Yugui Lian · NCT06698757
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.